Form 8-K - Current report:
SEC Accession No. 0001628280-21-009177
Filing Date
2021-05-06
Accepted
2021-05-06 08:13:01
Documents
16
Period of Report
2021-05-06
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20210506.htm   iXBRL 8-K 38310
2 EX-99.1 a991pressreleasedatedmay62.htm EX-99.1 86031
8 x4logo1.jpg GRAPHIC 9468
  Complete submission text file 0001628280-21-009177.txt   292678

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20210506.xsd EX-101.SCH 2423
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT xfor-20210506_cal.xml EX-101.CAL 710
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xfor-20210506_def.xml EX-101.DEF 1643
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20210506_lab.xml EX-101.LAB 25998
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20210506_pre.xml EX-101.PRE 13731
9 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20210506_htm.xml XML 11812
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 21895896
SIC: 2836 Biological Products, (No Diagnostic Substances)